Search results for: microscopic polyangiitis

Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes

Arthritis & Rheumatology | June 1, 2016

A variety of immune and nonimmune pathophysiologic mechanisms causing the disruption of alveolar capillaries with bleeding into the alveolar spaces can lead to diffuse alveolar hemorrhage (DAH). Immune-mediated mechanisms can cause DAH with or without the presence of capillaritis. The antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) syndromes—granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)—are the…

Case Report: Interstitial Lung Disease with Positive ANCA Test

Sara Tedeschi, MD | October 13, 2015

“Worst of all is the pain in my calves,” she said. “It feels like burning deep inside.” So began my first encounter with a 69-year-old woman who was referred to rheumatology clinic for evaluation of two months of constitutional symptoms and a positive ANCA test, which had been ordered by her primary care doctor. Her…

Why Rheumatologist–Pulmonologist Collaboration Is Essential

Vanessa Caceres | June 15, 2015

Although close collaboration with a variety of specialists outside of rheumatology is important, you could make the case for rheumatologists and pulmonologists having to work together even more closely. If lung symptoms are severe and not under control, the results could be fatal. However, the question sometimes is when to refer—even when there are not…

ANCA-Associated Vasculitis in Systemic Sclerosis

Carmen Busca Arenzana, MR, Ander Mayor-Ibarguren, MR, Amara Pieren-Salazar, MR, Natalia Martin-Suñe, MD, Isabel Esteban-Rodríguez, MD, Juan José Ríos-Blanco, MD, & Francisco Arnalich-Fernández, MD | October 1, 2014

A case report

ACR/ARHP Annual Meeting 2012: Cyclophosphamide and Rituximab Both Viable Treatment Options for ANCA-Associated Vasculitis

Mary Beth Nierengarten | February 1, 2013

Rituximab established as the drug of choice in patients with severe disease relapse, though cyclophosphamide may still play an important role for some patients, say rheumatologists

Maintenance of Remission in ANCA-Associated Vasculitis

Paul A. Monach, MD, PhD | September 5, 2012

Relapses are common, but difficult to predict and prevent.

ACR/ARHP Annual Scientific Meeting Plenary Highlights Targets and Treatments for Several Diseases

Vanessa Caceres | April 6, 2012

Promising therapeutic targets for rheumatic diseases were the focus of a plenary session here at the ACR/ARHP 2011 Annual Scientific Meeting in November. Presenters discussed discoveries and treatments for systemic sclerosis, rheumatoid arthritis, vasculitis, and Behçet’s disease.